Literature DB >> 7526574

Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine.

L A Sawyer1, J McInnis, A Patel, A D Horne, P Albrecht.   

Abstract

High-potency inactivated poliovirus vaccine (eIPV) was combined with diphtheria-tetanus-pertussis (DTP) vaccine containing thimerosal as a preservative to simulate the performance of a potential tetravalent vaccine. Neither type 1 nor type 3 poliovirus antigens appeared to be affected by thimerosal after exposure for 1 h at 37 degrees C as measured by enzyme-linked immunosorbent assay (ELISA). One epitope on the type 2 antigen was damaged within 5 min of exposure; however, the overall potency was unchanged when measured using a polyclonal antibody preparation. Exposure to thimerosal at 37 degrees C decreased the potency of all three poliovirus types to well below the level caused by heat deterioration alone in 1-2 days and to 0% after 16-17 days. At 25 degrees C, the potency of type 1 poliovirus decreased by 46% in 1 day, whereas poliovirus types 2 and 3 were stable for 1 week. Storage of eIPV at 4 degrees C in the presence of thimerosal reduced the potency of type 1 poliovirus antigen to undetectable levels after 4-6 months. Type 2 and 3 antigens were less markedly affected by 8 months of exposure to thimerosal at 4 degrees C. The loss of potency of type 1 as measured by ELISA was paralleled by a reduced level of neutralizing antibodies in mice injected with these preparations. The results obtained from testing eIPV in combination with DTP and thimerosal were generally similar to those obtained using eIPV with thimerosal. It remains to be seen to what extent thimerosal will affect the immunogenicity of eIPV in humans when injected as combined eIPV-DTP vaccine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526574     DOI: 10.1016/0264-410x(94)90296-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Misconceptions about the new combination vaccine.

Authors:  Helen Bedford; David Elliman
Journal:  BMJ       Date:  2004-08-21

Review 2.  Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries.

Authors:  Kutub Mahmood; Sonia Pelkowski; Deborah Atherly; Robert D Sitrin; John J Donnelly
Journal:  Hum Vaccin Immunother       Date:  2013-06-20       Impact factor: 3.452

3.  Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine.

Authors:  Heleen Kraan; Rimko Ten Have; Larissa van der Maas; Gideon Kersten; Jean-Pierre Amorij
Journal:  Vaccine       Date:  2016-07-26       Impact factor: 3.641

4.  Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine.

Authors:  Kawaljit Kaur; Jian Xiong; Nishant Sawant; Sanjeev Agarwal; John M Hickey; David A Holland; Tarit K Mukhopadhyay; Joseph R Brady; Neil C Dalvie; Mary Kate Tracey; Kerry R Love; J Christopher Love; David D Weis; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2020-12-03       Impact factor: 3.534

5.  Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens.

Authors:  Nishant Sawant; Kawaljit Kaur; David A Holland; John M Hickey; Sanjeev Agarwal; Joseph R Brady; Neil C Dalvie; Mary Kate Tracey; M Lourdes Velez-Suberbie; Stephen A Morris; Shaleem I Jacob; Daniel G Bracewell; Tarit K Mukhopadhyay; Kerry R Love; J Christopher Love; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2020-12-05       Impact factor: 3.534

Review 6.  Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Authors:  Edward Pk Parker; Natalie A Molodecky; Margarita Pons-Salort; Kathleen M O'Reilly; Nicholas C Grassly
Journal:  Expert Rev Vaccines       Date:  2015-07-09       Impact factor: 5.217

Review 7.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

8.  Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens.

Authors:  Sanjeev Agarwal; John M Hickey; David McAdams; Jessica A White; Robert Sitrin; Lakshmi Khandke; Stanley Cryz; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2019-10-04       Impact factor: 3.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.